GlassScriptPhysician profile
Eugene L Wong
NPI 1942308580
$9,139.78
in general payments reported to CMS, 2019-2025
28 companies · $1,488 in 2025
The $1,488 reported for 2025 was more than what 96% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,053 · 2020: $983 · 2021: $1,480 · 2022: $1,032 · 2023: $2,222 · 2024: $881 · 2025: $1,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,132 · Consulting Fee: $1,407 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,132.02 |
| Consulting Fee | $1,407.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,643.79 | 2020-2024 | Wainua |
| Janssen Pharmaceuticals, INC | $1,396.55 | 2019-2024 | Xarelto |
| Maquet Cardiopulmonary Gmbh | $800.00 | 2025 | Hls Set |
| Abbvie INC. | $702.71 | 2022-2025 | Dalvance, Avycaz, Teflaro |
| Becton, Dickinson and Company | $672.00 | 2019-2025 | Site-Rite, Powerglide |
| C. R. Bard, INC. & Subsidiaries | $625.00 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $569.18 | 2023-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Inari Medical, INC. | $446.60 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Bard Peripheral Vascular, INC. | $300.00 | 2019 | |
| Pfizer INC. | $271.47 | 2019-2023 | |
| Incyte Corporation | $251.51 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $184.98 | 2020-2023 | Zeposia |
| Cepheid | $170.00 | 2025 | Xpert Xpress Strep A |
| Merck Sharp & Dohme LLC | $163.79 | 2021-2023 | Zerbaxa |
| Abbott Laboratories | $156.52 | 2019-2025 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $137.00 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $125.00 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2023 | Austedo Xr |
| Paratek Pharmaceuticals, INC. | $68.26 | 2024 | Nuzyra |
| Irhythm Technologies, INC. | $57.36 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Novartis Pharmaceuticals Corporation | $49.22 | 2022 | |
| Harmony Biosciences LLC | $47.70 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.86 | 2019 | |
| Celgene Corporation | $37.56 | 2023 | Camzyos |
| Scpharmaceuticals INC. | $24.96 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $24.56 | 2024 | Arcalyst |
| Convatec INC. | $23.90 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.30 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.